File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Risk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients
  • Basic View
  • Metadata View
  • XML View
TitleRisk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients
 
AuthorsCheng, VCC1
Yam, WC1
Woo, PCY1
Lau, SKP1
Hung, IFN1
Wong, SPY1
Cheung, WC1
Yuen, KY1
 
KeywordsImmunocompromised Host
Bone Marrow Transplantation - immunology
Immunosuppressive Agents - administration & dosage
Lymphocyte Count
 
Issue Date2003
 
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/10096/index.htm
 
CitationEuropean Journal Of Clinical Microbiology And Infectious Diseases, 2003, v. 22 n. 10, p. 597-602 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s10096-003-0998-z
 
AbstractThe risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20-109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672±315 cells/μl vs. 1,328±467 cells/μl; P<0.001), and to exhibit a greater surge in lymphocyte counts (627±465 cells/μl vs. 225±216 cells/ μl; P<0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.
 
ISSN0934-9723
2013 Impact Factor: 2.544
 
DOIhttp://dx.doi.org/10.1007/s10096-003-0998-z
 
ISI Accession Number IDWOS:000186035600004
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorCheng, VCC
 
dc.contributor.authorYam, WC
 
dc.contributor.authorWoo, PCY
 
dc.contributor.authorLau, SKP
 
dc.contributor.authorHung, IFN
 
dc.contributor.authorWong, SPY
 
dc.contributor.authorCheung, WC
 
dc.contributor.authorYuen, KY
 
dc.date.accessioned2008-05-22T04:19:50Z
 
dc.date.available2008-05-22T04:19:50Z
 
dc.date.issued2003
 
dc.description.abstractThe risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20-109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672±315 cells/μl vs. 1,328±467 cells/μl; P<0.001), and to exhibit a greater surge in lymphocyte counts (627±465 cells/μl vs. 225±216 cells/ μl; P<0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.
 
dc.description.naturepostprint
 
dc.format.extent122809 bytes
 
dc.format.extent1902 bytes
 
dc.format.mimetypeapplication/pdf
 
dc.format.mimetypetext/plain
 
dc.identifier.citationEuropean Journal Of Clinical Microbiology And Infectious Diseases, 2003, v. 22 n. 10, p. 597-602 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s10096-003-0998-z
 
dc.identifier.doihttp://dx.doi.org/10.1007/s10096-003-0998-z
 
dc.identifier.epage602
 
dc.identifier.hkuros87975
 
dc.identifier.isiWOS:000186035600004
 
dc.identifier.issn0934-9723
2013 Impact Factor: 2.544
 
dc.identifier.issue10
 
dc.identifier.openurl
 
dc.identifier.pmid14508660
 
dc.identifier.scopuseid_2-s2.0-0242329701
 
dc.identifier.spage597
 
dc.identifier.urihttp://hdl.handle.net/10722/48642
 
dc.identifier.volume22
 
dc.languageeng
 
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/10096/index.htm
 
dc.publisher.placeGermany
 
dc.relation.ispartofEuropean Journal of Clinical Microbiology and Infectious Diseases
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThe original publication is available at www.springerlink.com
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subjectImmunocompromised Host
 
dc.subjectBone Marrow Transplantation - immunology
 
dc.subjectImmunosuppressive Agents - administration & dosage
 
dc.subjectLymphocyte Count
 
dc.titleRisk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Cheng, VCC</contributor.author>
<contributor.author>Yam, WC</contributor.author>
<contributor.author>Woo, PCY</contributor.author>
<contributor.author>Lau, SKP</contributor.author>
<contributor.author>Hung, IFN</contributor.author>
<contributor.author>Wong, SPY</contributor.author>
<contributor.author>Cheung, WC</contributor.author>
<contributor.author>Yuen, KY</contributor.author>
<date.accessioned>2008-05-22T04:19:50Z</date.accessioned>
<date.available>2008-05-22T04:19:50Z</date.available>
<date.issued>2003</date.issued>
<identifier.citation>European Journal Of Clinical Microbiology And Infectious Diseases, 2003, v. 22 n. 10, p. 597-602</identifier.citation>
<identifier.issn>0934-9723</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/48642</identifier.uri>
<description.abstract>The risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20-109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P&lt;0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672&#177;315 cells/&#956;l vs. 1,328&#177;467 cells/&#956;l; P&lt;0.001), and to exhibit a greater surge in lymphocyte counts (627&#177;465 cells/&#956;l vs. 225&#177;216 cells/ &#956;l; P&lt;0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.</description.abstract>
<format.extent>122809 bytes</format.extent>
<format.extent>1902 bytes</format.extent>
<format.mimetype>application/pdf</format.mimetype>
<format.mimetype>text/plain</format.mimetype>
<language>eng</language>
<publisher>Springer Verlag. The Journal&apos;s web site is located at http://link.springer.de/link/service/journals/10096/index.htm</publisher>
<relation.ispartof>European Journal of Clinical Microbiology and Infectious Diseases</relation.ispartof>
<rights>The original publication is available at www.springerlink.com</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject>Immunocompromised Host</subject>
<subject>Bone Marrow Transplantation - immunology</subject>
<subject>Immunosuppressive Agents - administration &amp; dosage</subject>
<subject>Lymphocyte Count</subject>
<title>Risk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0934-9723&amp;volume=22&amp;issue=1&amp;spage=597&amp;epage=602&amp;date=2003&amp;atitle=Risk+factors+for+development+of+paradoxical+response+during+antituberculosis+therapy+in+HIV-negative+patients</identifier.openurl>
<description.nature>postprint</description.nature>
<identifier.doi>10.1007/s10096-003-0998-z</identifier.doi>
<identifier.pmid>14508660</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0242329701</identifier.scopus>
<identifier.hkuros>87975</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0242329701&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>22</identifier.volume>
<identifier.issue>10</identifier.issue>
<identifier.spage>597</identifier.spage>
<identifier.epage>602</identifier.epage>
<identifier.isi>WOS:000186035600004</identifier.isi>
<publisher.place>Germany</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/48642/1/87975.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong